Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin after out-of-hospital cardiac arrest
ACTRN12624001183572Phase 2Not yet recruiting
- Sponsor
- Alfred Health
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cardiac arrest (SCA) and hypoxic-ischemic encephalopathy (HIE) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Composite of adverse events. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
cardiac arrest (SCA)hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on ACTRN12624001183572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001183572.